Detalhe da pesquisa
1.
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
Eur J Haematol;
111(5): 715-721, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37501508
2.
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Haematologica;
104(4): 797-804, 2019 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30467205
3.
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.
Br J Haematol;
159(5): 608-12, 2012 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23043283
4.
Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study.
Exp Hematol;
44(1): 38-49.e1, 2016 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26325331